Psoriasis Clinical Trial

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Summary

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of plaque psoriasis (PsO) for ≥ 6 months
Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs)
Deemed by Investigator to be eligible for phototherapy or systemic therapy
Psoriatic plaques must cover ≥ 10% of body surface area at baseline
Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline

Exclusion Criteria:

Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)
Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment
Any significant acute or chronic medical illness

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

120

Study ID:

NCT05730725

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 53 Locations for this study

See Locations Near You

Total Skin and Beauty Dermatology Center, PC
Birmingham Alabama, 35205, United States More Info
James Krell, Site 0006
Contact
205-380-6149
Alliance Dermatology
Phoenix Arizona, 85032, United States
Raoof MD
Encino California, 91436, United States More Info
TOORAJ RAOOF, Site 0012
Contact
818-788-5060
First OC Dermatology - Fountain Valley
Fountain Valley California, 92708, United States More Info
Vivian Laquer, Site 0005
Contact
714-925-1778
Center For Dermatology Clinical Research, Inc.
Fremont California, 94538, United States More Info
Sunil Dhawan, Site 0002
Contact
510-599-4750
Dermatology Research Associates - Howard Sofen, MD
Los Angeles California, 90045, United States More Info
Howard Sofen, Site 0001
Contact
Wallace Skin & Body Institute
Los Angeles California, 90056, United States More Info
Paul Wallace, Site 0016
Contact
Southern California Dermatology, Inc
Santa Ana California, 92701, United States More Info
Jennifer Soung, Site 0003
Contact
714-474-2174
Coral Gables Dermatology & Aesthetics
Coral Gables Florida, 33134, United States
Renstar Medical Research
Ocala Florida, 34470, United States More Info
Ashley Cauthen, Site 0032
Contact
352-629-5800
Dermatology Specialists Research - Indiana
Clarksville Indiana, 47129, United States More Info
Megan Vissing, Site 0044
Contact
Northeast Dermatology Associates, P.C. - Beverly
Beverly Massachusetts, 01915, United States More Info
David Greenstein, Site 0004
Contact
Allcutis Research, LLC - 155 Borthwick
Portsmouth New Hampshire, 03801, United States More Info
Abel Jarell, Site 0007
Contact
Duke Dermatology Clinic - Clinic 3K
Durham North Carolina, 27710, United States More Info
John Murray, Site 0055
Contact
919-949-9607
Case Western Reserve University
Cleveland Ohio, 44106, United States More Info
Neil Korman, Site 0008
Contact
University Hospitals Cleveland Medical Center
Cleveland Ohio, 44106, United States More Info
Francisco Kerdel, Site 0013
Contact
Palmetto Clinical Trial Services, LLC - Greenville
Greenville South Carolina, 29615, United States More Info
John Humeniuk, Site 0014
Contact
864-295-9085
Center for Clinical Studies (CCS) - Webster/Clear Lake Location
Webster Texas, 77598, United States More Info
Stephen Tyring, Site 0011
Contact
713-528-8818
Premier Clinical Research
Spokane Washington, 99202, United States
Local Institution - 0024
Brisbane Queensland, 4102, Australia More Info
Site 0024
Contact
Local Institution - 0019
Carlton Victoria, 3053, Australia More Info
Site 0019
Contact
Local Institution - 0045
Pascoe Vale South Victoria, 3044, Australia More Info
Site 0045
Contact
Local Institution - 0034
Barrie Ontario, L4M 7, Canada More Info
Site 0034
Contact
Local Institution - 0020
Hamilton Ontario, L8L 3, Canada More Info
Site 0020
Contact
Local Institution - 0041
London Ontario, N6A 2, Canada
Local Institution - 0015
Richmond Hill Ontario, L4C 9, Canada More Info
Site 0015
Contact
Local Institution - 0030
Toronto Ontario, M2N 3, Canada More Info
Site 0030
Contact
Local Institution - 0022
Novy Jicin CZ, 741 0, Czechia More Info
Site 0022
Contact
Local Institution - 0028
Ostrava MO, 70200, Czechia More Info
Site 0028
Contact
Local Institution - 0018
Prague , 100 0, Czechia More Info
Site 0018
Contact
Local Institution - 0021
Praha 1 , 11000, Czechia More Info
Site 0021
Contact
Local Institution - 0052
Reims Marne, 51100, France More Info
Site 0052
Contact
Local Institution - 0038
Martigues , 13500, France More Info
Site 0038
Contact
Local Institution - 0036
Rouen , 76031, France More Info
Site 0036
Contact
Local Institution - 0053
Saint-Priest-En-Jarez , 42270, France More Info
Site 0053
Contact
Local Institution - 0048
Toulon , 83000, France More Info
Site 0048
Contact
Local Institution - 0049
Sapporo-Shi Hokkaido, 064-0, Japan More Info
Site 0049
Contact
Local Institution - 0051
Fukuoka-shi , 814-0, Japan More Info
Site 0051
Contact
Local Institution - 0023
Itabashi-Ku , 173-8, Japan More Info
Site 0023
Contact
Local Institution - 0042
Itabashi-Ku , 173-8, Japan More Info
Site 0042
Contact
Local Institution - 0026
Nagoya-Shi , 467-8, Japan More Info
Site 0026
Contact
Local Institution - 0027
Tsu City , 514-8, Japan More Info
Site 0027
Contact
Local Institution - 0035
Wroclaw DS, 50-56, Poland More Info
Site 0035
Contact
Local Institution - 0039
Lodz LD, 90-26, Poland More Info
Site 0039
Contact
Local Institution - 0033
Lodz LD, 90-41, Poland More Info
Site 0033
Contact
Local Institution - 0043
Warszawa MZ, 01-14, Poland More Info
Site 0043
Contact
Local Institution - 0040
Warszawa MZ, 01-81, Poland
Local Institution - 0017
Warszawa MZ, 02-96, Poland More Info
Site 0017
Contact
Local Institution - 0025
Lodz , 90-43, Poland More Info
Site 0025
Contact
Local Institution - 0031
Wroclaw , 51-68, Poland More Info
Site 0031
Contact
Local Institution - 0037
Barcelona , 08040, Spain More Info
Site 0037
Contact
Local Institution - 0050
Hinckley LEC, LE10 , United Kingdom More Info
Site 0050
Contact
Local Institution - 0046
Leytonstone LND, E11 1, United Kingdom More Info
Site 0046
Contact
Local Institution - 0054
London LND, N20 9, United Kingdom More Info
Site 0054
Contact
Local Institution - 0047
Liverpool Merseyside, L1 9E, United Kingdom More Info
Site 0047
Contact

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

120

Study ID:

NCT05730725

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.